Thinking About Buying Canopy Growth? You May Want to Wait for This 1 Thing to Happen First.

Canopy Growth (CGC) faces a critical regulatory catalyst as the DEA weighs rescheduling cannabis from Schedule I to Schedule III following President Trump's executive order directing the agency to act. Rescheduling would allow CGC to consolidate its U.S. affiliate and eliminate Section 280E tax restrictions that currently prevent cannabis companies from deducting ordinary business expenses.

However, historical patterns suggest caution. Past regulatory announcements in the cannabis sector have triggered short-lived rallies followed by sharp selloffs, leaving traders who bought ahead of news underwater. The recommendation: wait for the DEA decision before entering a position rather than speculating on the timing or outcome.

The rescheduling catalyst represents a structural shift for the industry, but it remains a binary event with uncertain timing. Trump's executive order accelerates the timeline, yet the DEA has not committed to a specific announcement date.